Bristol-Myers Squibb: In the Pipeline
 
 
 

In the Pipeline | May 1, 2016

Compound /
Generic Name

Brand Name

Phase

Modality /
Compound Type

Disease
Areas

IKur Inhibitor
2
Small Molecule
Cardiovascular
Nitroxyl Donor
2
Small Molecule
Cardiovascular
PAR4 Antagonist
1
Small Molecule
Cardiovascular
Apixaban
M
Small Molecule
Cardiovascular
Factor XIa Inhibitor
1
Small Molecule
Cardiovascular
PEG-FGF21 (2)
1
Biologic
Fibrotic Diseases
Galectin-3 Inhibitor
1
Small Molecule
Fibrotic Diseases
LPA1 Antagonist
2
Small Molecule
Fibrotic Diseases
Pentraxin-2
2
Biologic
Fibrotic Diseases
PEG-FGF21 (1)
2
Biologic
Fibrotic Diseases
Anti-Myostatin
1
Biologic
Genetically Defined         Diseases
Anti-eTau
1
Biologic
Genetically Defined         Diseases
Urelumab (Anti-CD137)
2
Biologic
Immuno-Oncology
Anti-CSF1R
1
Biologic
Immuno-Oncology
Anti-GITR
1
Biologic
Immuno-Oncology
IDO Inhibitor
1
Small Molecule
Immuno-Oncology
Anti-LAG-3
2
Biologic
Immuno-Oncology
Elotuzumab
M
Biologic
Immuno-Oncology
PROSTVAC
3
Biologic
Immuno-Oncology
Nivolumab
M
Biologic
Immuno-Oncology
Ipilimumab
M
Biologic
Immuno-Oncology
Lirilumab (Anti-KIR)
2
Biologic
Immuno-Oncology
BTK Inhibitor
2
Small Molecule
Immunoscience
Lulizumab (Anti-CD28)
2
Biologic
Immunoscience
Abatacept
M
Biologic
Immunoscience
Anti-CD40
1
Biologic
Immunoscience
Belatacept
M
Biologic
Immunoscience
Anti-CD40L
2
Biologic
Immunoscience
Anti-PD-L1
1
Biologic
Immunoscience
TYK2 Inhibitor
1
Small Molecule
Immunoscience
Anti-Fucosyl GM1
1
Biologic
Oncology
Ulocuplumab (Anti-CXCR4)
1
Biologic
Oncology
Mesothelin-ADC
1
Biologic
Oncology
Dasatinib
M
Small Molecule
Oncology
Anti-HER2
1
Biologic
Oncology
BET Inhibitor
1
Small Molecule
Oncology
reset >

Explore Our Pipeline


Customize View

Development Phase
1 - Phase I
2 - Phase II
3 - Phase III
M - Marketed Product       Development
Modality/Compound Type
Biologic
Small Molecule
Disease Areas

* Virology assets removed with sale of virology R&D pipeline to ViiV Healthcare on Feb 22. Bristol-Myers Squibb continues development for HCV assets including Daklinza, Sunvepra and beclabuvir (NS5B Non Nuc) in select markets.

Please click on product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI™, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.

Phase I – clinical trials investigating safety of an investigational medicine in a small number of human subjects.

Phase II – clinical trials investigating dosing, safety and efficacy of an investigational medicine in a small number of patients who have the disease or condition under study.

Phase III – clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. For purposes of this chart, this includes the regulatory approval process prior to receiving marketing approval in the first major market.

Marketed Product Development – clinical trials investigating new uses or formulations regarding medicines that have already received regulatory approval for at least one indication in a major market.

Like any other scientific endeavor, clinical testing of novel drug compounds is a complex, time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.

 
 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.